- Home
- SVRA vs KBDC Comparison
SVRA vs KBDC Comparison
Compare SVRA & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SVRA | KBDC |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 918.9M |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SVRA | KBDC |
|---|---|---|
| Price | $5.13 | $14.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $7.33 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.2M | 287.7K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 13.46% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $193.84 |
| Revenue Next Year | $430.87 | $9.00 |
| P/E Ratio | ★ N/A | $8.46 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $13.06 |
| 52 Week High | $7.01 | $16.40 |
Technical Indicators
Market Signals| Indicator | SVRA | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 52.78 |
| Support Level | $4.95 | $14.01 |
| Resistance Level | $6.15 | $14.30 |
| Average True Range (ATR) | 0.29 | 0.30 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 16.85 | 43.33 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
About KBDC Kayne Anderson BDC Inc.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.